MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,779K
Net Income
-$33,530K
Net Profit Margin
-1884.77%
EPS
-$0.58
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and collaboration revenue
1,779
1,294
348
795
Research and development
10,817
10,160
8,357
9,356
General and administrative
4,342
4,205
4,767
4,596
Impairment of right-of-use asset
-
-
0
494
Total operating expenses
15,159
14,365
13,124
14,446
Loss from operations
-13,380
-13,071
-12,776
-13,651
Interest income
807
910
710
423
Change in fair value of derivative tranche liability
-20,930
-6,188
-28,170*
-1,800
Other expense
-
-
48*
-
Other (expense) income
-27
18
-
-71
Total other (expense) income, net
-20,150
-5,260
-27,508
-1,448
Net loss attributable to common stockholders
-33,530
-18,331
-40,284
-15,099
Other comprehensive income (loss)
0
0
0
-
Total comprehensive loss
-33,530
-18,331
-40,284
-15,099
Basic EPS
-0.58
-0.32
-0.747
-0.55
Diluted EPS
-0.58
-0.32
-0.747
-0.55
Basic Average Shares
57,929,662
57,923,674
53,935,009
27,274,721
Diluted Average Shares
57,929,662
57,923,674
53,935,009
27,274,721
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$33,530K
(-166.39%↓ Y/Y)
Net loss
attributable to common...
-$33,530K
(-166.39%↓ Y/Y)
Total other (expense)
income, net
-$20,150K
(-4669.16%↓ Y/Y)
Loss from operations
-$13,380K
(-2.70%↓ Y/Y)
Interest income
$807K
(78.15%↑ Y/Y)
Research and
collaboration revenue
$1,779K
(18.84%↑ Y/Y)
Change in fair value of
derivative tranche...
-$20,930K
Total operating
expenses
$15,159K
(4.36%↑ Y/Y)
Other (expense)
income
-$27K
(-125.00%↓ Y/Y)
Research and development
$10,817K
(4.58%↑ Y/Y)
General and
administrative
$4,342K
(3.83%↑ Y/Y)
Buy us a coffee
Camp4 Therapeutics Corp (CAMP)
Camp4 Therapeutics Corp (CAMP)